Phase II trial of the pan-deacetylase inhibito... [Leuk Lymphoma. 2012] - PubMed

Save items

loading

Related citations in PubMed

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. [Leuk Lymphoma. 2012]
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Offidani M, Polloni C, Cavallo F, Liberati AM, Ballanti S, Pulini S, Catarini M, Alesiani F, Corvatta L, Gentili S, et al. Leuk Lymphoma. 2012 Sep; 53(9):1722-7. Epub 2012 Mar 16.
Review Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. [Leuk Res. 2010]
Review Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S, Dimopoulos MA, Lonial S. Leuk Res. 2010 Sep; 34(9):1111-8. Epub 2010 May 15.
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. [Cancer Chemother Pharmacol. 2012]
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
Shapiro GI, Frank R, Dandamudi UB, Hengelage T, Zhao L, Gazi L, Porro MG, Woo MM, Lewis LD. Cancer Chemother Pharmacol. 2012 Feb; 69(2):555-62. Epub 2011 Nov 6.
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland. [Swiss Med Wkly. 2007]
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
Freimann H, Calderoni A, Cornu P, Olie R. Swiss Med Wkly. 2007 Jun 2; 137(21-22):317-22.
Review Treatment of relapsed and refractory myeloma. [Curr Hematol Malig Rep. 2009]
Review Treatment of relapsed and refractory myeloma.
Kaufman J, Gleason C, Lonial S. Curr Hematol Malig Rep. 2009 Apr; 4(2):99-107.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent i...
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Leuk Lymphoma. 2012 Sep ;53(9):1820-3. doi: 10.3109/10428194.2012.661175. Epub 2012 Mar 1 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.

Comment in

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information